12.83
price down icon3.02%   -0.40
after-market Dopo l'orario di chiusura: 13.00 0.17 +1.33%
loading
Precedente Chiudi:
$13.23
Aprire:
$13.41
Volume 24 ore:
338.77K
Relative Volume:
0.80
Capitalizzazione di mercato:
$460.02M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-7.56%
1M Prestazione:
+51.12%
6M Prestazione:
+202.59%
1 anno Prestazione:
+130.76%
Intervallo 1D:
Value
$12.53
$13.60
Intervallo di 1 settimana:
Value
$12.53
$14.02
Portata 52W:
Value
$2.88
$14.46

Bioage Labs Inc Stock (BIOA) Company Profile

Name
Nome
Bioage Labs Inc
Name
Telefono
510-806-1445
Name
Indirizzo
5885 HOLLIS STREET, EMERYVILLE
Name
Dipendente
64
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
BIOA's Discussions on Twitter

Confronta BIOA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
BIOA
Bioage Labs Inc
12.83 474.36M 0 0 0 0.00
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
125.92 55.45B 9.40B 2.65B 2.24B 5.935
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.62 49.25B 29.63B 260.53M 5.51B 0.0788
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.00 45.02B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
30.95 35.81B 16.88B 666.71M 251.19M 0.6132
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
496.72 20.98B 3.08B 1.24B 1.07B 25.61

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-12-05 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2025-10-22 Aggiornamento Citigroup Neutral → Buy
2025-02-28 Iniziato William Blair Mkt Perform
2024-12-10 Downgrade Morgan Stanley Overweight → Underweight
2024-12-09 Downgrade Citigroup Buy → Neutral
2024-12-09 Downgrade Jefferies Buy → Hold
2024-10-21 Iniziato Citigroup Buy
2024-10-21 Iniziato Jefferies Buy
2024-10-21 Iniziato Morgan Stanley Overweight
Mostra tutto

Bioage Labs Inc Borsa (BIOA) Ultime notizie

pulisher
Jan 01, 2026

Can BioAge Labs Inc. stock deliver sustainable ROEQuarterly Earnings Review & Maximum Profit Growth - bollywoodhelpline.com

Jan 01, 2026
pulisher
Dec 27, 2025

BioAge Labs upgraded to equal weight from underweight at Morgan Stanley - MSN

Dec 27, 2025
pulisher
Dec 25, 2025

BIOA INVESTORS: Kirby McInerney LLP Reminds BioAge Labs, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm - TMX Newsfile

Dec 25, 2025
pulisher
Dec 24, 2025

BioAge Labs (NASDAQ:BIOA) Sets New 52-Week HighStill a Buy? - MarketBeat

Dec 24, 2025
pulisher
Dec 23, 2025

Cash per share of BioAge Labs, Inc. – FWB:Y7G - TradingView — Track All Markets

Dec 23, 2025
pulisher
Dec 22, 2025

BioAge Labs, Inc.(NasdaqGS: BIOA) added to NASDAQ Biotechnology Index - marketscreener.com

Dec 22, 2025
pulisher
Dec 21, 2025

BioAge Labs announces positive phase 1 trial results - MSN

Dec 21, 2025
pulisher
Dec 20, 2025

BioAge Labs (BIOA) Price Target Increased by 24.14% to 12.24 - Nasdaq

Dec 20, 2025
pulisher
Dec 20, 2025

Is BioAge Labs Inc. stock dividend yield sustainableJuly 2025 Catalysts & Real-Time Volume Trigger Notifications - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Can BioAge Labs Inc. stock continue upward trendMarket Activity Summary & Verified Momentum Stock Ideas - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Why BioAge Labs Inc. (Y7G) stock is listed among top recommendationsQuarterly Market Review & Risk Controlled Daily Trade Plans - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

What makes BioAge Labs Inc. stock attractive to growth fundsJuly 2025 Levels & Precise Swing Trade Alerts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

Can BioAge Labs Inc. stock withstand economic slowdown2025 Technical Overview & Technical Confirmation Alerts - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

How analysts rate BioAge Labs Inc. stock today2025 Volume Leaders & High Accuracy Investment Signals - DonanımHaber

Dec 19, 2025
pulisher
Dec 15, 2025

Bioage Labs Earnings Notes - Trefis

Dec 15, 2025
pulisher
Dec 13, 2025

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Globe and Mail

Dec 13, 2025
pulisher
Dec 13, 2025

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool

Dec 13, 2025
pulisher
Dec 13, 2025

Bioage Labs Stock Rockets 52% With 8-Day Winning Streak - Trefis

Dec 13, 2025
pulisher
Dec 12, 2025

Paul Rubin Sells 18,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat

Dec 12, 2025
pulisher
Dec 11, 2025

BioAge Labs CMO Paul D. Rubin Sells 18,000 Shares - TradingView — Track All Markets

Dec 11, 2025
pulisher
Dec 11, 2025

[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan

Dec 11, 2025
pulisher
Dec 09, 2025

Officer Rubin Files To Sell 18,000 Of BioAge Labs Inc [BIOA] - TradingView — Track All Markets

Dec 09, 2025
pulisher
Dec 08, 2025

Morgan Stanley Upgrades BioAge Labs (BIOA) - Nasdaq

Dec 08, 2025
pulisher
Dec 08, 2025

BioAge Labs (BIOA) Competitors and Alternatives 2025 - MarketBeat

Dec 08, 2025
pulisher
Dec 07, 2025

Volume Recap: How BioAge Labs Inc stock reacts to Fed rate cutsFed Meeting & Technical Pattern Recognition Alerts - BỘ NỘI VỤ

Dec 07, 2025
pulisher
Dec 06, 2025

Paul Rubin Sells 68,897 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat

Dec 06, 2025
pulisher
Dec 06, 2025

BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen - MarketBeat

Dec 06, 2025
pulisher
Dec 05, 2025

BioAge Labs CMO Paul D. Rubin Sells All Common Stock Holdings - TradingView

Dec 05, 2025
pulisher
Dec 05, 2025

Officer Rubin Sells 68,897 ($701.9K) Of BioAge Labs Inc [BIOA] - TradingView

Dec 05, 2025
pulisher
Dec 05, 2025

BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data - Investing.com South Africa

Dec 05, 2025
pulisher
Dec 05, 2025

How BioAge Labs Inc. stock reacts to Fed rate cutsShort Setup & Fast Gain Stock Trading Tips - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial - Investing.com Nigeria

Dec 05, 2025
pulisher
Dec 05, 2025

Is BioAge Labs Inc. stock a safe haven assetQuarterly Earnings Summary & Safe Entry Zone Identification - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

Why BioAge Labs Inc. stock remains undervaluedCEO Change & Smart Money Movement Alerts - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioAge Labs, Inc. (BIOA) and Insulet (PODD) - The Globe and Mail

Dec 05, 2025
pulisher
Dec 05, 2025

How BioAge Labs Inc. (Y7G) stock stacks up against competitorsInsider Selling & Daily Chart Pattern Signal Reports - Newser

Dec 05, 2025
pulisher
Dec 04, 2025

Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs - TipRanks

Dec 04, 2025
pulisher
Dec 04, 2025

Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛

Dec 04, 2025
pulisher
Dec 04, 2025

Officer Rubin Files To Sell 68,897 Of BioAge Labs Inc [BIOA] - TradingView

Dec 04, 2025
pulisher
Dec 04, 2025

Will BioAge Labs Inc. (Y7G) stock outperform global peersCEO Change & Safe Capital Investment Plans - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Merger Talk: Is BioAge Labs Inc stock a safe haven assetPortfolio Growth Summary & Weekly Watchlist of Top Performers - BỘ NỘI VỤ

Dec 04, 2025
pulisher
Dec 04, 2025

BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues - marketscreener.com

Dec 04, 2025
pulisher
Dec 04, 2025

BioAge Reports Positive Interim Phase 1 Data For BGE-102; Shares Rise - Nasdaq

Dec 04, 2025
pulisher
Dec 04, 2025

BioAge Labs Announces Positive Phase 1 Trial Results - TipRanks

Dec 04, 2025

Bioage Labs Inc Azioni (BIOA) Dati Finanziari

Non sono disponibili dati finanziari per Bioage Labs Inc (BIOA). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_specialty_generic RGC
$20.54
price down icon 2.19%
$22.52
price down icon 0.49%
drug_manufacturers_specialty_generic RDY
$13.86
price down icon 1.28%
$140.60
price down icon 0.87%
$12.46
price up icon 0.08%
$496.72
price up icon 1.94%
Capitalizzazione:     |  Volume (24 ore):